In the FullSTEP® study, patients uncontrolled on basal insulin with or without OADs were randomized to either a stepwise approach or a full basal-bolus dosing arm. In the stepwise arm, patients added NovoLog® to their basal insulin at the patient-perceived largest meal of the day. After 11 weeks and 22 weeks, additional doses of NovoLog® were added, if A1C was ≥ 7%, to the next largest patient-perceived largest meals. In the full basal-bolus arm, NovoLog® was added at all 3 main meals from the start. The study found that there were significantly fewer hypoglycemic events with a stepwise regimen vs full basal-bolus.